AF
CORT icon

Amalgamated Financial’s Corcept Therapeutics CORT Stock Holding History

Amalgamated Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.02M Buy
+45,532
New +$969K 0.01% 1161

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's CORT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Corcept Therapeutics (CORT) in Q1 2022: 45,532 shares worth $1.02M. The stake represents 0.01% of the portfolio and ranks #1161 among its holdings.

228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • Amalgamated Financial held 45,532 shares of Corcept Therapeutics worth $1.02M as of Q1 2022.
  • Corcept Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Corcept Therapeutics made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1161 holding.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.